Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre

Publisher： Karger

E-ISSN： 1421-9875|35|1-2|91-100

ISSN： 0257-2753

Source： Digestive Diseases, Vol.35, Iss.1-2, 2017-02, pp. : 91-100

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Chemokines in Inflammatory Bowel Diseases

By  

Digestive Diseases, Vol. 28, Iss. 3, 2010-09 ,pp. : 386-394

Karger

Access to resources Recommend Favorite

Antibiotics and Inflammatory Bowel Diseases

By  

Digestive Diseases, Vol. 31, Iss. 3-4, 2013-11 ,pp. : 379-384

Karger

Access to resources Recommend Favorite

Surgery for Inflammatory Bowel Diseases

By  

Digestive Diseases, Vol. 21, Iss. 2, 2003-10 ,pp. : 168-179

Karger

Access to resources Recommend Favorite

Inflammatory Bowel Diseases 2003 – From Genetics to Biological Therapy

By  

Digestive Diseases, Vol. 21, Iss. 2, 2003-10 ,pp. : 83-84

Karger

Access to resources Recommend Favorite

The epidemiology of inflammatory bowel diseases in Finland

By Manninen Pia   Karvonen Anna-Liisa   Huhtala Heini   Rasmussen Martin   Collin Pekka  

Scandinavian Journal of Gastroenterology, Vol. 45, Iss. 9, 2010-09 ,pp. : 1063-1067

Informa Healthcare

Access to resources Recommend Favorite